Recombinant expression vector for expressing LL-37 polypeptide, recombinant lactococcus lactis, antiviral drug, construction method and application
The invention provides a recombinant expression vector for expressing LL-37 polypeptide, recombinant lactococcus lactis, an antiviral drug, a construction method and application, and belongs to the technical field of gene engineering. A skeleton plasmid for constructing the recombinant expression vector is PNZ8149; a fusion gene is inserted into the recombinant expression vector; the nucleotide sequence of the fusion gene is shown as SEQ ID NO: 1. The recombinant expression vector disclosed by the invention can be efficiently expressed in lactococcus lactis, and the LL-37 obtained by expression can effectively inhibit SARS coronavirus and SARS-CoV2 coronavirus. The invention also provides recombinant lactococcus lactis containing the recombinant expression vector in the scheme. According to the recombinant lactococcus lactis disclosed by the invention, an antiviral polypeptide drug LL-37 can be input into a human body in an oral form, the antiviral effect is good, and the production cost is low..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 07. Aug. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
JIN WANZHU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN111500615 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005724716 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005724716 | ||
| 003 | DE-627 | ||
| 005 | 20230503165411.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA005724716 | ||
| 035 | |a (EPA)CN111500615 | ||
| 035 | |a (EPA)71869420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a JIN WANZHU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant expression vector for expressing LL-37 polypeptide, recombinant lactococcus lactis, antiviral drug, construction method and application |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-08-07, Last update posted on www.tib.eu: 2022-04-09, Last updated: 2023-02-09 | ||
| 520 | |a The invention provides a recombinant expression vector for expressing LL-37 polypeptide, recombinant lactococcus lactis, an antiviral drug, a construction method and application, and belongs to the technical field of gene engineering. A skeleton plasmid for constructing the recombinant expression vector is PNZ8149; a fusion gene is inserted into the recombinant expression vector; the nucleotide sequence of the fusion gene is shown as SEQ ID NO: 1. The recombinant expression vector disclosed by the invention can be efficiently expressed in lactococcus lactis, and the LL-37 obtained by expression can effectively inhibit SARS coronavirus and SARS-CoV2 coronavirus. The invention also provides recombinant lactococcus lactis containing the recombinant expression vector in the scheme. According to the recombinant lactococcus lactis disclosed by the invention, an antiviral polypeptide drug LL-37 can be input into a human body in an oral form, the antiviral effect is good, and the production cost is low. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG HANLIN |4 aut | |
| 700 | 0 | |a JIANG XIAOXIAO |4 aut | |
| 700 | 0 | |a ZHENG AIHUA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 07. Aug. |
| 773 | 1 | 8 | |g year:2020 |g day:07 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71869420/publication/CN111500615A1?q=CN111500615 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 07 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 07 |c 08 | ||